Interaction of docetaxel ('Taxotere') with human P-glycoprotein

Japanese Journal of Cancer Research

Volumn 90, Issue 12, 1999, Pages 1380-1386

  Shirakawa, Katsuro ^a   Takara, Kohji ^a   Tanigawara, Yusuke ^b   Aoyama, Nobuo ^a   Kasuga, Masato ^a   Komada, Fusao ^a,c   Sakaeda, Toshiyuki ^a   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c JOSAI UNIVERSITY   (Japan)

Author keywords

'Taxotere'; Docetaxel; Multidrug resistance; P glycoprotein; Transport

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; COMPLEMENTARY DNA; CYCLOSPORIN A; DAUNORUBICIN; DOCETAXEL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; VALSPODAR; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL TRANSPORT; CONTROLLED STUDY; DRUG ACCUMULATION; EPITHELIUM CELL; GENETIC TRANSFECTION; KIDNEY EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0033373639     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00723.x     Document Type: Article

References (32)

1. Ringel, I. and Horwitz, S. B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst., 83, 288-291 (1991).
2. Clarke, S. J. and Rivory, L. P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet., 36, 99-114 (1999).
3. Dumontet, C. and Sikic, B. I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17, 1061-1070 (1999).
4. Bissery, M. C., Guenard, D., Gueritte, V. F. and Lavelle, F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 51, 4845-4852 (1991).
5. Riou, J. F., Naudin, A. and Lavelle, F. Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Commun., 187, 164-170 (1992).
6. Garcia, P., Braguer, D., Carles, G., Khyari, S., Barra, Y., de Ines, C., Barasoain, I. and Briand, C. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother. Pharmacol., 34, 335-343 (1994).
7. Hill, B. T., Whelan, R. D., Shellard, S. A., McClean, S. and Hosking, L. K. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest. New Drugs, 12, 169-182 (1994).
8. Cortes, J. E. and Pazdur, R. Docetaxel. J. Clin. Oncol, 13, 2643-2655 (1995).
9. Schuller, J., Czejka, M., Kletzl, H., Wirth, M., Springer, B., Kriwanek, S., Terkola, R. and Schernthaner, G. Doxorubicin (DOX) and Taxotere (TXT): a pharmacokinetic (PK) study of the combination in advanced breast cancer (abstr.). Proc. Am. Soc. Clin. Oncol, 17, 205 (1998).
10. Shirazi, F., Bahrami, G., Fanaee, G., Lotfolahi, A., Rouini, M. R., Stewart, D. J., Tomiak, E., Delorme, F., Vernillet, L., Bruno, R. and Goel, R. Pharmacokinetic interactions of docetaxel and etoposide (abstr.). Proc. Am. Soc: Clin. Oncol., 17, 252 (1998).
11. 1). J. Pharmacol Exp. Ther., 263, 840-845 (1992).
12. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R. Human P-glyco-protein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem., 267, 24248-24252 (1992).
13. 1 cells transfected with human MDR1 gene. Biochem. Pharmacol., 53, 741-746 (1997).
14. Kusunoki, N., Takara, K., Tanigawara, Y., Yamauchi, A., Ueda, K., Komada, F., Ku, Y., Kuroda, Y., Saitoh, Y. and Okumura, K. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn. J. Cancer Res., 89, 1220-1228 (1998).
15. Takara, K., Tanigawara, Y., Komada, F., Nishiguchi, K., Sakaeda, T. and Okumura, K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol. Pharm. Bull., 22 (1999), in press.
16. Horio, M., Pastan, I., Gottesman, M. M. and Handler, J. S. Transepithelial transport of vinblastine by kidney-derived cell lines. Application of a new kinetic model to estimate in situ Km of the pump. Biochim. Biophys. Acta. 1027, 116-122 (1990).
17. Evers, R., Zaman, G. J. R., Deemter, L., Jansen, H., Calafat, J., Oomen, L. C. J. M., Oude Elferink, R. P. J., Borst, P. and Schinkel, A. H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest., 97, 1211-1218 (1996).
18. Royer, I., Monsarrat, B., Sonnier, M., Wright, M. and Cresteil, T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res., 56. 58-65 (1996).
19. Marre, F., Sanderink, G. J., Sousa, G., Gaillard, C., Martinet, M. and Rahmani, R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res., 56, 1296-1302 (1996).
20. Monsarrat, B., Royer, I., Wright, M. and Cresteil, T. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull. Cancer, 84, 125-133 (1997).
21. Urien, S., Barre, J., Morin, C., Paccaly, A., Montay, G. and Tillement, J. P. Docetaxel serum protein binding with high affinity to alphal-acid glycoprotein. Invest. New Drugs, 14, 147-151 (1996).
22. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84, 7735-7738 (1987).
23. Bosch, I. and Croop, J. P-Glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta. 1288, F37-F54 (1996).
24. Endicott, J. A. and Ling, V. The biochemistry of P-glyco-protein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171 (1989).
25. Gottesman, M. M. and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993).
26. Baggetto, L. G. Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies. J. Bioenerg. Biomembr., 29, 401-413 (1997).
27. Stein, W. D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev., 77, 545-590 (1997).
28. Aszalos, A. and Ross, D. D. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res., 18, 2937-2944 (1998).
29. Samuels, B. L., Mick, R., Vogelzang, N. J., Williams, S. F., Schilsky, R. L., Sufa, A. R., O'Brien, S. M. and Ratain, M. J. Modulation of vinblastine resistance with cyclosporin: a phase I study. Clin. Pharmacol. Ther., 54, 421-429 (1993).
30. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C. and Bunting, P. Phase 1 pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53. 4837-4842 (1993).
31. Rushing, D. A., Raber, S. R., Rodvold, K. A., Piscitelli, S. C., Plank, G. S. and Tewksbury, D. A. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer, 74, 834-841 (1994).
32. Bartlett, N. L., Lum, B. L., Fischer, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J. and Sikic, B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 12, 835-842 (1994).